On Oct. 14, Vir Biotechnology announced a collaboration agreement with Gilead Sciences worth up to $1.88 billion to explore and develop new cancer treatments for solid tumors. Vir will receive a $90 million upfront payment and up to $45 million in near-term preclinical milestones, and will use its PRO-XTEN masking technology and dAIsy AI platform to design drug candidates.